Analysis of hepatic CD4+, CD8+, CD20+, and CD57+ T lymphocytes in chronic hepatitis B patients with different HBeAg status

Analysis of hepatic CD4+, CD8+, CD20+, and CD57+ T lymphocytes in chronic hepatitis B patients with different HBeAg status

ObjectiveTo investigate the relationship of hepatic immune cells (CD4+, CD8+, CD20+, and CD57+ T lymphocytes) with liver pathology and clinical relevance in chronic hepatitis B (CHB) patients with different HBeAg status. MethodsA total of 70 CHB patients admitted to our hospital from January 2008 to...

Full description

Bibliographic Details
Main Author:	XIAN Yongchao
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2015-04-01
Series:	Linchuang Gandanbing Zazhi
Subjects:	hepatitis B chronic; hepatitis B e antigens; T-lymphocyte subsets

Similar Items

Significance of changes in hepatic histology from patients with HBeAg(+) or HBeAg(-) chronic hepatitis B and normal or mildly elevated alanine aminotransferase
by: LAN Lin
Published: (2015-04-01)

Viral mutations and natural course of HBeAg negative chronic hepatitis B virus infection.
Published: (2001)

Correlation analysis of percentages of T lymphocyte subsets and CD4+CD25+ regulatory T cells and HBV DNA level in peripheral blood of chronic hepatitis B patients
by: LI Caidong
Published: (2015-04-01)

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01)

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
by: Hu Yao-ren, et al.
Published: (2014-03-01)

Relationship between HBV DNA and HBeAg in serum and HBcAg and inflammation grade in liver tissue among patients with chronic hepatitis B
by: LIU Xingxiang
Published: (2013-12-01)

Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients
by: Fatima A Ahmed, et al.
Published: (2019-01-01)

Relation of hepatitis B core antigen expression with histological activity, serum HBeAg, and HBV DNA levels
by: Aysegul Sari, et al.
Published: (2011-01-01)

Value of FibroScan in diagnosis of hepatic fibrosis in patients with HBeAg-negative chronic hepatitis B
by: LUO Junhua
Published: (2014-07-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
by: Ho Soo Chun, et al.
Published: (2021-07-01)

Evaluation of telbivudine’s efficacy for treating HBeAg-positive chronic B hepatitis patients and identification of its predictive factors by logistic regression analysis
by: GUO Ruyi
Published: (2013-02-01)

Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors
by: LOU Xin, et al.
Published: (2018-05-01)

Clinical efficacy of telbivudine and interferon in treatment of HBeAg-positive chronic hepatitis B: a comparative study
by: LI Huoyan
Published: (2015-04-01)

Chronic viral HBeAg-negative hepatitis B: Epidemiological, clinical and biochemical characteristics in an outpatient descriptive cohort in Burkina Faso
by: Eric Nagaonlé Somé, et al.
Published: (2021-07-01)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
by: Wen Jia, et al.
Published: (2019-05-01)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
by: Cai S, et al.
Published: (2018-04-01)

Influence of quantitative changes in HBeAg on the therapeutic efficacy of antiviral drugs
by: XIE Zhiwei
Published: (2013-02-01)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
by: Byung-Cheol Song, et al.
Published: (2014-12-01)

Efficacy of pegylated interferon α-2a in HBeAg-negative chronic hepatitis B patients and its influencing factors
by: LIU Zhihua
Published: (2015-05-01)

Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B
by: MA Yanhong
Published: (2013-08-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B: preliminary comparative study
by: YAN Haiming
Published: (2013-07-01)

Differential profiles of T-cell subsets are present in peripheral blood of patients with various progressive forms of hepatitis B infection
by: WANG Wei
Published: (2013-04-01)

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
by: Ott Jördis J, et al.
Published: (2012-06-01)

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
by: Anna D. Kosinska, et al.
Published: (2021-07-01)

HBV genotype distribution and its relationship with serum HBV DNA level and HBeAg expression among patients with chronic hepatitis B in southern Zhejiang Province, China
by: ZHOU Lianlian
Published: (2014-10-01)

A combination of the percentages of IFN-γ+CD4+T cells and granzyme B+CD19+B cells is associated with acute hepatic rejection: a case control study
by: Ji-Qiao Zhu, et al.
Published: (2021-05-01)

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-IFN-α 2a in HBeAgpositive CHB Patients
by: Ji Yong-jian, et al.
Published: (2013-09-01)

Quantitative HBsAg and Qualitative HBeAg Predicts Intrauterine Placental Infection and Umbilical Blood Cord in Pregnant Women
by: Erry Gumilar Dachlan, et al.
Published: (2020-10-01)

Relationship between HBV DNA level and pathological changes of liver tissue in HBeAg-negative patients with chronic HBV infection
by: CHEN Nian
Published: (2013-06-01)

Viral immunochemical status of HBeAg, HBeAb, Anti-HIV, and Anti-HCV in hepatitis B surface antigen-seronegative anicteric malaise patients
by: Mathew Folaranmi Olaniyan, et al.
Published: (2018-01-01)

Distribution of CD8 and CD20 lymphocytes in chronic periapical inflammatory lesions
by: Philippi Christine Kalvelage, et al.
Published: (2003-01-01)

Possible immunochemical pattern of anti-HCV, HBeAg, HBsAg HBeAb, and HIV-1 p24 in newly infected Mycobacterium pulmonary tuberculosis patients
by: Mathew Folaranmi Olaniyan, et al.
Published: (2019-01-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection
by: Louise O. Downs, et al.
Published: (2019-06-01)

Changes of B cell subsets characterized with CD27 and CD38 phenotypes in peripheral blood of myasthenia gravis patients
by: Jian⁃hua JIANG, et al.
Published: (2019-11-01)

Impact of pegylated interferon versus conventional interferon on the change in peripheral CD4+CD25high T cells in patients with chronic hepatitis B
by: WANG Haiyan
Published: (2018-01-01)

The unfolded protein response (UPR) in cultured cells expressing either wild-type or mutant hepatitis B e antigen (HBeAG) of the hepaptitis B virus(HBV)
by: Bhoola, Nimisha Harshadrai
Published: (2014)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)